Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Noboru Yamamoto

Showing results (41-50 of 437) with videos related to

Pageof 44
Sort By:
The Tohoku Journal of Experimental Medicine|September 6, 2007
Problems with registration-directed clinical trials for lung cancer in JapanIkuo Sekine, Hiroshi Nokihara, Noboru Yamamoto, et al.
Japanese Journal of Clinical Oncology|March 6, 2009
Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumorsNoboru Yamamoto, Yasuhide Yamada, Yutaka Fujiwara, et al.
Cancer Chemotherapy and Pharmacology|January 21, 2014
Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumorsHiroshi Wakui, Noboru Yamamoto, Shinji Nakamichi, et al.
Bioorganic & Medicinal Chemistry|December 31, 2005
A credit-card library approach for disrupting protein-protein interactionsYang Xu, Jin Shi, Noboru Yamamoto, et al.
Cancer Chemotherapy and Pharmacology|August 3, 2015
Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug-drug interactionMasanori Motonaga, Noboru Yamamoto, Yoshinori Makino, et al.
ESMO Open|April 12, 2020
Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trialsYutaka Fujiwara, Aya Kuchiba, Takafumi Koyama, et al.
Cancer Chemotherapy and Pharmacology|April 28, 2009
A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancerNoboru Yamamoto, Tomohide Tamura, Takayasu Kurata, et al.
ESMO Open|May 17, 2018
Reduction in nephrotoxicities using short hydration for chemotherapy containing cisplatin: a consecutive analysis of 467 patients with thoracic malignanciesMidori Tanaka, Hidehito Horinouchi, Yasushi Goto, et al.
Cancer Science|December 2, 2023
Progress report of a cross-organ and biomarker-based basket-type clinical trial: BELIEVE TrialYayoi Ando, Tatsunori Shimoi, Kuniko Sunami, et al.
Statistical Applications in Genetics and Molecular Biology|May 19, 2026
Performance of the permutation test approach with base calling errors for detecting changes in variant allele frequencies in ctDNA for a single patientAya Kuchiba, Jo Nishino, Shinichi Yachida, et al.
Pageof 44

Showing results (41-50 of 437) with videos related to

Sort By:
Pageof 44
The Tohoku Journal of Experimental Medicine|September 6, 2007
Problems with registration-directed clinical trials for lung cancer in JapanIkuo Sekine, Hiroshi Nokihara, Noboru Yamamoto, et al.
Japanese Journal of Clinical Oncology|March 6, 2009
Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumorsNoboru Yamamoto, Yasuhide Yamada, Yutaka Fujiwara, et al.
Cancer Chemotherapy and Pharmacology|January 21, 2014
Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumorsHiroshi Wakui, Noboru Yamamoto, Shinji Nakamichi, et al.
Bioorganic & Medicinal Chemistry|December 31, 2005
A credit-card library approach for disrupting protein-protein interactionsYang Xu, Jin Shi, Noboru Yamamoto, et al.
Cancer Chemotherapy and Pharmacology|August 3, 2015
Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug-drug interactionMasanori Motonaga, Noboru Yamamoto, Yoshinori Makino, et al.
ESMO Open|April 12, 2020
Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trialsYutaka Fujiwara, Aya Kuchiba, Takafumi Koyama, et al.
Cancer Chemotherapy and Pharmacology|April 28, 2009
A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancerNoboru Yamamoto, Tomohide Tamura, Takayasu Kurata, et al.
ESMO Open|May 17, 2018
Reduction in nephrotoxicities using short hydration for chemotherapy containing cisplatin: a consecutive analysis of 467 patients with thoracic malignanciesMidori Tanaka, Hidehito Horinouchi, Yasushi Goto, et al.
Cancer Science|December 2, 2023
Progress report of a cross-organ and biomarker-based basket-type clinical trial: BELIEVE TrialYayoi Ando, Tatsunori Shimoi, Kuniko Sunami, et al.
Statistical Applications in Genetics and Molecular Biology|May 19, 2026
Performance of the permutation test approach with base calling errors for detecting changes in variant allele frequencies in ctDNA for a single patientAya Kuchiba, Jo Nishino, Shinichi Yachida, et al.
Pageof 44